Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties. It is thought to exert its effects by enhancing the inhibitory effects of gamma-aminobutyric acid (GABA).
## Primary Indications
* Adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in patients 2 years of age and older.
* Off-label use for other seizure types, including absence seizures, myoclonic seizures, and focal seizures.
## Adult Dosing
* **LGS:** Initial dose: 5 mg twice daily. Titrate by 5-10 mg/day every week to a maximum of 20 mg twice daily.
* **Other Seizures (Off-label):** Dosing is highly variable and depends on seizure type and patient response. Typical starting doses range from 5-10 mg once or twice daily, with titration up to a maximum of 20 mg twice daily or higher in some cases, under specialist supervision.
## Pediatric Dosing
* **LGS (2 years and older):** Initial dose: 2.5 mg twice daily. Titrate by 2.5-5 mg/day every week to a maximum of 10 mg twice daily for patients weighing less than 30 kg, and 20 mg twice daily for patients weighing 30 kg or more.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. Consider lower doses and slower titration.
* **Renal Impairment:** Use with caution. No specific dose adjustments are established, but monitoring for increased CNS effects is recommended.
## Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe respiratory insufficiency.
* Severe hepatic insufficiency.
## Adverse Effects
* **Common:** Somnolence, drowsiness, fatigue, ataxia, drooling, constipation, decreased appetite, insomnia, aggression, irritability, mood changes, upper respiratory tract infections.
* **Serious:** Severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), suicidal behavior and ideation, respiratory depression, dependence and withdrawal symptoms, cognitive impairment, paradoxical reactions.
## Key Drug Interactions
* **CNS Depressants (alcohol, opioids, other sedatives):** Additive CNS depression. Monitor closely.
* **CYP2C19 Inhibitors (e.g., fluconazole, omeprazole):** May increase clobazam levels. Consider dose reduction.
* **CYP2C19 Inducers (e.g., rifampin):** May decrease clobazam levels. Consider dose increase.
* **Phenytoin:** Clobazam may increase phenytoin levels. Monitor phenytoin levels.
* **Stimulants (e.g., amphetamines):** May decrease the effectiveness of clobazam.
## Monitoring
* Seizure frequency and severity.
* Signs and symptoms of CNS depression (somnolence, dizziness, confusion).
* Signs of withdrawal upon discontinuation.
* Behavioral changes, including suicidal ideation.
* Signs of severe skin reactions.
* Drug interactions with concomitant medications.
## Clinical Pearls
* Clobazam is a Schedule IV controlled substance.
* Taper slowly when discontinuing to avoid withdrawal symptoms.
* Patients and caregivers should be advised of the risk of somnolence and the importance of avoiding activities requiring mental alertness until the drug's effects are known.
* Due to the risk of serious skin reactions, patients should be educated to discontinue clobazam and seek immediate medical attention if a rash develops.
***
**Disclaimer:** This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant guidelines before making any treatment decisions.
